Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F11 | P03951 | 3/20 | 0.34 |
| ▸ | F2 | P00734 | 2/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.34 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.34 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 4/20 | 0.33 |
| ▸ | P4HB | P07237 | 1/20 | 0.33 |
| ▸ | LPL | P06858 | 3/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2136697 | 0.74 | LIPG (0.46) | F11F2PRSS1PRSS2PRSS3 | |
| SCHEMBL4753530 | 0.73 | LIPG (0.40) | F11F2PRSS1PRSS2PRSS3 | |
| SCHEMBL1400888 | 0.72 | LIPG (0.36) | F11F2PRSS1PRSS2PRSS3 | |
| SCHEMBL1130443 | 0.72 | DAO (0.46) | F11F2PRSS1PRSS2PRSS3 | |
| SCHEMBL1558987 | 0.72 | PDGFRB (0.37) | F11F2PRSS1PRSS2PRSS3 | |
| SCHEMBL59027 | 0.72 | F11 (0.39) | F11F2PRSS1PRSS2PRSS3 | |
| SCHEMBL5263215 | 0.71 | CES2 (0.38) | — | |
| SCHEMBL59978 | 0.71 | ROCK1 (0.42) | F11F2PRSS1PRSS2PRSS3 | |
| SCHEMBL58297 | 0.71 | AAK1 (0.44) | F11F2PRSS1PRSS2PRSS3 | |
| SCHEMBL1554719 | 0.71 | DGAT1 (0.37) | F11F2PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9145414-B2 | 1,2,4-triazine-6-carboxamide derivative | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2015-09-29 | — | — | US | disclosed |
| US-20140343038-A1 | 1,2,4-TRIAZINE-6-CARBOXAMIDE DERIVATIVE | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2014-11-20 | — | — | US | disclosed |
| EP-2762476-A1 | 1,2,4-TRIAZINE-6-CARBOXAMIDE DERIVATIVE | Taiho Pharmaceutical Co., Ltd. (JP) | 2014-08-06 | — | — | EP | disclosed |
| EP-1968568-A2 | INHIBITORS OF Akt ACTIVITY | SmithKline Beecham Corporation (US) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007076423-A2 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343038-A1 | 1,2,4-TRIAZINE-6-CARBOXAMIDE DERIVATIVE | SYK, BTK, JAK2 | F11 905/4885F2 1582/4885PRSS1 2582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.